“Untreatable” cases of cystic fibrosis may be undermined by new therapy
An experimental drug suggests that therapy for currently untreatable cases of cystic fibrosis is “clearly achievable”.
List view / Grid view
An experimental drug suggests that therapy for currently untreatable cases of cystic fibrosis is “clearly achievable”.
Cell Line Development and cell culture process teams, are you geared up to leverage the vast amount of data generated by high-throughput?
Researchers have identified 38 drugs that could be repurposed to treat COVID-19 through a strategy involving virtual screening and cell-based assays.
Researchers in Japan propose that the antimalarial drug mefloquine could be repurposed to effectively treat SARS-CoV-2.
Drug analysis at the Francis Crick Institute and University of Dundee has revealed 15 potential antivirals that could lead to new COVID-19 treatments.
A screening campaign has revealed that small molecule inhibitors of the SOX 11 oncogene are toxic to mantle cell lymphoma in vitro.
We demonstrate the power of waveRAPID in streamlining the kinetic characterisation of large numbers of drug hit compounds, with results comparable to traditional surface plasmon resonance (SPR) and high reproducibility.
A small molecule found in a cell-based ultra-high-throughput screening campaign was shown to treat diabetes in cells and mice.
With the COVID-19 pandemic ongoing, new therapeutic drugs to combat SARS-CoV-2 are still required. In this article, Professor Arvind Patel from the Medical Research Council (MRC) – Centre for Virus Research (CVR) at the University of Glasgow spoke with Drug Target Review’s Victoria Rees to discuss the work being done…
In this article, Drug Target Review’s Victoria Rees explores a new screening platform that assesses the biological activity of molecules to identify potential drugs. Using their new technique, researchers from the US National Institutes of Health (NIH) identified potential COVID-19 therapeutics.
A major challenge during high-throughput and fragment screening is the potential for identifying ‘frequent hitters’ – compounds that affect unrelated targets. Matthew Lloyd from the University of Bath explains why these hits can arise during drug discovery and how machine learning could be the answer to identifying these compounds.
This ebook has articles on the use of screening to identify COVID-19 drugs and how assessing compound activity could accelerate drug discovery.
Researchers have developed a cross-validation high-throughput screening method to accelerate the identification of SHP2 inhibitors.
Scientists have found four clinically approved drugs and nine compounds with the potential to be repurposed as therapeutics for COVID-19.
A new high-throughput screening platform has been used to identify two compounds with antiviral activity against the Nipah and Hendra viruses.